Table 2.
A summary of all recommendations of cases with reported results according to cancer type (n = 933 and 718 recommendations)
| All (n = 993) | Colorectal (n = 201) | Breast (n = 107) | Urology (n = 97) | Sarcoma (n = 166) | HPB (n = 102) | Lung (n = 41) | Glioma (n = 68) | Blood (n = 30) | Melanoma (n = 48) | Upper GI (n = 25) | H&N (n = 6) | Gynae (n = 23) | Paediatric (n = 17) | CUP (n = 2) | p value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with reported results | ||||||||||||||||
| No recommendation | 381 (38.4) | 71 (35.3) | 25 (23.4) | 43 (44.3) | 108 (65.1) | 36 (35.3) | 8 (19.5) | 24 (35.3) | 18 (60.0) | 18 (37.5) | 12 (48.0) | 2 (33.3) | 9 (39.1) | 6 (35.3) | 1 (50.0) | <0.0001 |
| Recommendation | 552 (61.6) | 130 (64.7) | 82 (76.6) | 54 (55.6) | 58 (34.9) | 66 (64.7) | 33 (80.5) | 44 (64.7) | 12 (40.0) | 30 (62.5) | 13 (52.0) | 4 (66.7) | 14 (60.9) | 11 (64.7) | 1 (50.0) | <0.0001 |
| Participants with therapeutic recommendationsb | ||||||||||||||||
| Treatment (Licensed) | 24 (4.3) | 3 (2.3) | 4 (4.9) | 4 (7.4) | 0(0) | 2 (3.0) | 2 (6.1) | 1 (2.3) | 0(0) | 5 (16.7) | 1 (7.7) | 0(0) | 2 (14.3) | 0(0) | 0(0) | 0.0234 |
| Treatment (Unlicensed) | 19 (3.4) | 1 (0.8) | 6 (7.3) | 4 (7.4) | 0(0) | 0(0) | 1 (3.0 | 0 (0.0) | 0(0) | 5 (16.7) | 0(0) | 1 (25.0) | 0(0) | 1 (9.1) | 0(0) | <0.0001 |
| Clinical Trial | 274 (49.6) | 60 (46.2) | 34 (41.5) | 21 (38.9) | 26 (44.8) | 46 (69.7) | 22 (66.7) | 31 (70.5) | 4 (33.3) | 15 (50.0) | 5 (38.5) | 1 (25.0) | 8 (57.1) | 0(0) | 0(0) | <0.0001 |
| High TMB report | 96 (17.4) | 48 (36.9) | 3 (3.7) | 11 (20.4) | 0(0) | 4 (6.1) | 6 (18.2) | 3 (6.8) | 0(0) | 13 (43.3) | 3 (23.1) | 0(0) | 4 (28.6) | 0(0) | 1 (100.0) | <0.0001 |
| Participants with other recommendations | ||||||||||||||||
| DPYD | 56 (10.1) | 8 (6.2) | 11 (13.4) | 7 (13.0) | 9 (15.5) | 0(0) | 8 (24.2) | 0(0) | 6 (50.0) | 2 (6.7) | 1 (7.7) | 1 (25.0) | 1 (7.1) | 2 (18.2) | 0(0) | <0.0001 |
| Clinical genetics | 85 (15.4) | 20 (15.4) | 27 (32.9) | 9 (16.7) | 11 (19.0) | 7 (10.6) | 1 (3.0) | 3 (6.8) | 2 (16.7) | 1 (3.3) | 0(0) | 0(0) | 0(0) | 4 (36.4) | 0(0) | <0.0001 |
| Not validated | 86 (15.6) | 6 (4.6) | 14 (17.1) | 8 (14.8) | 18 (31.0) | 11 (16.7) | 5 (15.2) | 9 (20.5) | 2 (16.7) | 3 (10.0) | 4 (30.8) | 2 (50.0) | 0(0) | 4 (36.4) | 0(0) | 0.0110 |
| Participants with therapeutic recommendationsc | 377/552 (68.3) | 110/130 (84.6) | 43/82 (52.4) | 33/54 (61.1) | 26/58 (44.8) | 50/66 (75.8) | 25/33 (75.8) | 34/44 (77.2) | 4/12 (33.3) | 27/48 (56.3) | 9/13 (69.2) | 2/4 (50.0) | 12/14 (85.7) | 1/11 (9.1) | 1/1 (100.0) | <0.0001 |
| Therapeutic recommendationsb | ||||||||||||||||
| Treatment (Licensed) | 26 (3.6) | 3 (1.8) | 5 (4.6) | 4 (5.6) | 0(0) | 2 (2.5) | 2 (3.6) | 1 (1.7) | 0(0) | 6 (12.2) | 1 (6.7) | 0(0) | 2 (12.5) | 0(0) | 0(0) | 0.059 |
| Treatment (Unlicensed) | 21 (2.9) | 1 (0.6) | 6 (5.5) | 4 (5.6) | 0(0) | 0(0) | 1 (1.8) | 0(0) | 0(0) | 7 (14.3) | 0(0) | 1 (20.0) | 0(0) | 1 (9.1) | 0(0) | <0.0001 |
| Clinical Trial | 348 (48.5) | 77 (47.2) | 43 (39.4) | 28 (39.4) | 30 (44.1) | 56 (70.0) | 33 (58.9) | 44 (73.3) | 4 (28.6) | 17 (34.7) | 6 (40.0) | 1 (20.0) | 9 (56.3) | 0(0) | 0(0) | <0.0001 |
| TMB report | 96 (13.4) | 48 (29.4) | 3 (2.8) | 11 (15.5) | 0(0) | 4 (5.0) | 6 (10.7) | 3 (5.0) | 0(0) | 13 (26.5) | 3 (20.0) | 0(0) | 4 (25.0) | 0(0) | 1 (100.0) | <0.0001 |
| Other recommendations | ||||||||||||||||
| DPYD | 56 (7.8) | 8 (4.9) | 11 (10.1) | 7 (9.9) | 9 (13.2) | 0(0) | 8 (14.3) | 0(0) | 6 (42.9) | 2 (4.1) | 1 (6.7) | 1 (20.0) | 1 (6.3) | 2 (18.2) | 0(0) | <0.0001 |
| Clinical genetics | 85 (11.8) | 20 (13.3) | 27 (24.8) | 9 (12.7) | 11 (16.2) | 7 (8.8) | 1 (1.8) | 3 (5.0) | 2 (14.3) | 1 (2.0) | 0(0) | 0(0) | 0(0) | 4 (36.4) | 0(0) | <0.0001 |
| Not validated | 86 (12.0) | 6 (3.7) | 14 (12.8) | 8 (11.3) | 18 (26.5) | 11 (13.8) | 5 (8.9) | 9 (15.0) | 2 (14.3) | 3 (6.10) | 4 (26.7) | 2 (40.0) | 0(0) | 4 (36.4) | 0(0) | <0.0001 |
| Total number of all recommendationsc | 718 | 163 | 109 | 71 | 68 | 80 | 56 | 60 | 14 | 49 | 15 | 5 | 16 | 11 | 1 | <0.0001 |
| Total number of all therapeutic recommendations | 491/718 (68.4) | 129/163 (79.1) | 57/109 (52.2) | 47/71 (66.2) | 30/68 (44.1) | 62/80 (77.5) | 42/56 (75.0) | 48/60 (80.0) | 4/14 (28.6) | 43/49 (87.8) | 10/15 (33.3) | 2/5 (40.0) | 15/16 (93.8) | 1/11 (9.1) | 1/1 (100.0) | <0.0001 |
Count (Percentage of total recommended action).
HPB hepatobiliary, Blood haematological, GI gastrointestinal tract, H&N head and neck, Gynae Gynaecological, CUP Cancer of Unknown Primary, DPYD dihydropyrimidine dehydrogenase polymorphism, TMB Tumour mutational burden.
aCount (Proportion of total indicated).
btherapeutic recommentations= trial, licensed or unlicensed treatment, high TMB.
cMultiple recommendations per participants were made for a proportion of this cohort.